Last reviewed · How we verify

NCT02973750

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer

Completed Last updated 26 January 2023
What this trial tests

trial testing Baseline Biopsy in Ovarian Cancer in 20 participants. Completed in 18 July 2020.

Timeline
20 October 2016
Primary endpoint
18 July 2020
18 July 2020

Quick facts

Lead sponsorH. Lee Moffitt Cancer Center and Research Institute
StatusCompleted
Study typeOBSERVATIONAL
Enrollment20
Start date20 October 2016
Primary completion18 July 2020
Estimated completion18 July 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, female only, with Ovarian Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

While significant progress has been made in the treatment and prognosis of ovarian cancer, this progress has mostly shown benefits for younger women. This study aims to understand two things: How body composition (the amount of muscle and water versus fat in in the body) affects the dose and side effects of chemotherapy; and the biological reason for the worse prognosis with aging. To get a good view of these effects, investigators are asking the help of both younger and older women for this project.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02973750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing